BioVie FY26 net loss widens to $22.1 million; operating expenses rise to $22.7 million
BIVI•FY26 results
- BioVie posted a net loss of USD 22.1 million, widening from USD 17.5 million a year earlier.
- Operating expenses rose to USD 22.7 million from USD 18.1 million, driven by higher R&D spending.
- R&D expenses climbed to USD 14 million from USD 9.3 million on increased Sunrise-PD and Long COVID Phase 2 activity.
- Cash and cash equivalents totaled USD 9 million, with working capital of USD 9.8 million as of June 30, 2026.
Clinical program updates
- Bezisterim SUNRISE-PD Phase 2b met prespecified endpoints; Long COVID Phase 2 topline results expected in late summer 2026.
